4D Molecular Therapeutics FDMT Operating margin
Operating margin at other companies
Other financials
Where this comes from
Calculated from 4D Molecular Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's operating margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's operating margin?
- 4D Molecular Therapeutics (FDMT) reported operating margin of -220.1% in Q1 2026.
- How has 4D Molecular Therapeutics's operating margin changed year-over-year?
- 4D Molecular Therapeutics's operating margin increased by 100.0% year-over-year, from -884,026.1% to -220.1%.
- What is the long-term trend for 4D Molecular Therapeutics's operating margin?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's operating margin has grown at a -12.0% compound annual growth rate (CAGR), from -388.4% to -204.5%.
- What does operating margin mean?
- Operating income as a percentage of revenue (trailing twelve months). Captures profitability from core operations after both cost of revenue and operating expenses, but before interest and taxes.